Status:
COMPLETED
A Study of Single Dose of ABT-333 in Healthy Male Adults
Lead Sponsor:
Abbott
Collaborating Sponsors:
Abbott Japan Co.,Ltd
Conditions:
HCV Infections
Eligibility:
MALE
20-50 years
Phase:
PHASE1
Brief Summary
The objectives of this study is to assess the safety, tolerability, and pharmacokinetics of blind, escalating, single, oral doses of ABT-333 under nonfasting conditions in healthy male adult in Japan.
Eligibility Criteria
Inclusion
- Subject has provided written consent.
- Subject is in general good health.
Exclusion
- See above for main selection criteria.
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT00919490
Start Date
June 1 2009
Last Update
October 25 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Site Reference ID/Investigator# 19102
Kagoshima, Japan, 890-0081